Table 2.
Compound | ED50 (μg kg−1; i.t.) | Dose (μg kg−1; i.t.) | TPD (mV) | n |
---|---|---|---|---|
Amiloride | 16 | 0 | −10.5±1.1 | 10 |
3.0 | −9.8±1.2 | 6 | ||
30 | −6.0±0.4a | 8 | ||
300 | −4.4±0.2a | 4 | ||
3000 | −4.3±0.4a | 4 | ||
Benzamil | 14 | 0 | −8.8±0.5 | 20 |
1.0 | −10.1±1.4 | 7 | ||
10 | −6.0±0.4 | 5 | ||
100 | −4.3±0.6a | 6 | ||
1000 | −3.0±0.5a | 6 | ||
10 000 | −2.9±0.9a | 6 | ||
CF552 | 0.2 | 0 | −10.5±1.0 | 9 |
0.01 | −9.8±0.9 | 4 | ||
0.1 | −7.8±0.9 | 4 | ||
1.0 | −7.1±0.4b | 4 | ||
10 | −5.1±0.3a | 4 | ||
100 | −5.2±0.4a | 6 | ||
EIPA | >300 | 0 | −9.7±1.3 | 5 |
300 | −10.0±0.6 | 5 | ||
Mean absolute tracheal potential difference values±s.e.mean obtained in groups of guinea-pigs dosed with either vehicle (0.2 mL 5% dextrose) or test compound by i.t. instillation. One-way ANOVA followed by Dunnett's multiple comparison test was used to test for differences between compound-treated and vehicle control groups.
P<0.01.
P<0.05.
EIPA was tested up to the limit of solubility in 5% dextrose.